Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-alpha Inhibition for Cancer and Autoimmune Disease.
Totzke, J., Gurbani, D., Raphemot, R., Hughes, P.F., Bodoor, K., Carlson, D.A., Loiselle, D.R., Bera, A.K., Eibschutz, L.S., Perkins, M.M., Eubanks, A.L., Campbell, P.L., Fox, D.A., Westover, K.D., Haystead, T.A.J., Derbyshire, E.R.(2017) Cell Chem Biol 24: 1029-1039.e7
- PubMed: 28820959 
- DOI: 10.1016/j.chembiol.2017.07.011
- Primary Citation of Related Structures:  
5V5N - PubMed Abstract: 
Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment ...